KOSDAQFood & Beverage238200

Bifido

₩2,245▼ 1.75%2026-11-18 close
Market Cap
₩18.4B
Turnover
₩7,421,575
Volume
3.4K
Shares out.
8.2M
PER
9.3×
PBR
0.4×
EPS
₩249
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Rebound, Losses Still Linger

Bifido returned to operating profit in 2025, and its sales have risen for two straight quarters since the 2026 first-quarter low. Operating losses over three consecutive quarters and competition during the shift to individually recognized functional ingredients remain open issues.

  1. 1

    Operating profit turned positive at KRW 1.4 billion in 2025, and sales of KRW 19.7 billion were the largest of the 2022 to 2025 period.

  2. 2

    Sales bottomed at KRW 2.5 billion in the first quarter of 2026, and the second and third quarters then recorded two straight increases.

  3. 3

    The company posted operating losses in three consecutive quarters from the first quarter to the third quarter of 2026, though the size of the losses narrowed each quarter.

  4. 4

    In April 2026 the company resolved to transfer land and buildings in Daechi-dong, Gangnam-gu, Seoul for KRW 25.4 billion, citing debt repayment and liquidity.

  5. 5

    Pending Ministry of Food and Drug Safety approvals for body-fat reduction and sensitive-skin immune improvement claims are cited as the next business variable.

02

Business structure

Bifido was founded in 1999 and listed on KOSDAQ in 2018 as a probiotics specialist. It manufactures and sells probiotic raw materials and health functional foods based on Bifidobacterium originally isolated from the intestines of Korean infants.

Its operations are split into finished-product and raw-material segments, and an explanation of its cumulative 2025 results credits sales growth in both segments for the improvement. Besides operating its own brand, the company also provides ODM manufacturing for other firms.

The company attributed the 2025 sales growth mainly to more domestic customers and higher overseas sales. It has been widening its overseas reach through trade shows, including Vitafoods India 2024. Analysts describe rising competition in the probiotics market.

Reports also link the first-half 2026 deterioration to lower finished-product and raw-material sales as the market shifts toward individually recognized probiotics.

As of the third quarter of 2025, the company was pursuing Ministry of Food and Drug Safety approvals for body-fat reduction and sensitive-skin immune improvement claims.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.7B-₩400M−10.1%
2025Q4₩4.8B₩400M7.4%
2026Q1₩2.5B-₩600M−23.9%
2026Q2₩3.6B-₩400M−11.4%
2026Q3₩4.3B-₩68,779,367−1.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩14.6B₩1.3B₩1.5B8.7%2.9%4.7%
2023₩18.6B-₩300M₩1.1B−1.8%2.1%38.7%
2024₩12.4B-₩4.5B-₩5.4B−36.4%−11.6%31.1%
2025₩19.7B₩1.4B-₩200M7.1%−0.4%33.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Bifido's reported results run from a 2024 operating loss as the trough, through a return to operating profit in 2025, to quarter-to-quarter swings in 2026.

Annual sales were KRW 14.6 billion in 2022, KRW 18.6 billion in 2023 (up 27.8% year on year), KRW 12.4 billion in 2024 (down 33.7%), and KRW 19.7 billion in 2025 (up 59.3%). Of the 2022 to 2025 period, 2025 was the largest year and 2024 the smallest.

Operating profit fell from KRW 1.26 billion in 2022 to an operating loss of KRW 344 million in 2023, and the loss widened to KRW 4.49 billion in 2024. Operating profit of KRW 1.4 billion in 2025 marked a return to profit. The operating margin moved from 8.7% in 2022 to -1.8% in 2023, -36.4% in 2024 and 7.1% in 2025.

Net income attributable to controlling shareholders was KRW 1.55 billion in 2022 and KRW 1.08 billion in 2023 (down 30.0%), then turned to a net loss of KRW 5.4 billion in 2024. The 2025 net loss narrowed to KRW 193 million, and the company has posted losses for two consecutive years, 2024 and 2025.

Net income including non-controlling interests followed the same direction, at a net loss of KRW 5.4 billion in 2024 and KRW 193 million in 2025. Operating cash flow went from negative KRW 716 million in 2024 to KRW 3.95 billion in 2025.

The debt ratio moved from 4.7% in 2022 to 38.7% in 2023, 31.1% in 2024 and 33.5% in 2025. At the end of 2025, total equity was KRW 45.9 billion and total liabilities were KRW 15.4 billion. On a quarterly basis, the third quarter of 2025 showed sales of KRW 3.71 billion and an operating loss of KRW 375 million.

The fourth quarter brought sales of KRW 4.83 billion (up 30.3% quarter on quarter) and operating profit of KRW 360 million, a return to profit, while the net loss attributable to controlling shareholders widened to KRW 914 million.

First-quarter 2026 sales fell to KRW 2.5 billion (down 48.3% quarter on quarter) with an operating loss of KRW 597 million.

Net income attributable to controlling shareholders nonetheless turned positive at KRW 2.67 billion, and the gap between the operating loss and this net income can be traced to non-operating items.

Second-quarter 2026 sales rose to KRW 3.6 billion (up 44.3%), with an operating loss of KRW 410 million and net income attributable to controlling shareholders of KRW 318 million.

Third-quarter 2026 sales reached KRW 4.27 billion (up 18.6% quarter on quarter and 15.3% year on year), with an operating loss of KRW 68.78 million and a net loss attributable to controlling shareholders of KRW 33.78 million.

Sales rose for two consecutive quarters, and the operating loss narrowed in both the second and third quarters. The sum of net income attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, was KRW 2.04 billion.

05

Industry analysis

The probiotics market where Bifido operates has many products and fast-intensifying competition. The company has built its strategy around patented Bifidobacterium strains as raw materials, and reports say it has pursued individually recognized raw-material registration for one of its strains.

Industry commentary holds that the market center is shifting toward ingredients with recognized functional claims as that system takes hold. In this shift, sales of the existing finished-product and raw-material segments declined, which is cited as a background to the weak first half of 2026.

Conversely, more domestic customers and higher overseas sales drove the 2025 recovery, suggesting that the effort to broaden sales channels has produced some effect. Overseas, the company pursued new probiotics markets by attending Vitafoods India in 2024.

Large competitors with wider distribution networks and bigger advertising budgets are present in the health-functional-food and lactic-acid-bacteria categories. Bifido's smaller sales scale may limit its ability to secure sales channels, which can be viewed as a weakness.

On the other hand, holding patented strains and functional recognition could be a point of differentiation in dealings with finished-product makers.

The speed at which this converts into sales depends on approval and customer timelines, so the strength of the industry backdrop is best gauged by the mix of raw-material and finished-product sales in the next annual report.

06

Outlook

The company has set out three directions. First, it is pursuing Ministry of Food and Drug Safety approval for body-fat reduction and sensitive-skin immune improvement claims, as of the third quarter of 2025.

Second, the land and buildings in Daechi-dong, Gangnam-gu, Seoul, which it resolved on April 9, 2026 to transfer for KRW 25.4 billion, are intended for debt repayment and securing liquidity, with the transfer reference date and registration date set for August 14, 2026.

Which debt the sale proceeds actually retired can be checked in the borrowings disclosure of the 2026 annual report. Third, reports describe a plan to expand overseas channels while also developing microbiome-based drugs.

On results, sales rose for two consecutive quarters in the second and third quarters of 2026 while the operating loss narrowed. The quarter in which the operating loss turns into operating profit has not been specified in any disclosure.

Whether the improvement lasts can be judged by whether quarterly sales hold at levels in the KRW 4 billion range and whether selling and administrative expenses grow more slowly than sales. Whether the finished-product and raw-material sales that were cited as the first-half weakness recover is another point to watch.

Approval outcomes under the individually recognized system could affect the terms of the raw-material business. After the asset sale, the debt ratio is the metric to watch, so the size of debt repayment and changes in cash flow are the next checks.

The 2026 fiscal year ends on December 31, 2026, which closes the fourth-quarter results, and the 2026 annual report will then present the full-year figures.

07

Valuation

PER
9.3×
PBR
0.4×
ROE
4.2%
EPS
₩249
BPS
₩5,979
Dividend per share
₩0

The share price trades at a level well below the company's book equity. All of the KRW 45.9 billion in total equity at the end of 2025 belongs to controlling shareholders, so how the discount to book value per share changes alongside results is the comparison point.

On an earnings basis, a net loss attributable to controlling shareholders remains even though operating profit turned positive in 2025, so the price-to-earnings relationship depends on how steadily net income accumulates.

The sum of net income attributable to controlling shareholders over the last four quarters was KRW 2.04 billion, and its quarter-to-quarter swings are wide, so multiples should be read with that range in mind. The dividend yield is below the industry average, and no dividend is being paid.

On assets, the property transfer is presented as a way to improve the capital structure, so whether the balance between equity and liabilities shifts in the next annual report is the check point.

Valuation is therefore best read as a factual comparison of the discount to net assets alongside whether profitability holds.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Financial Cushion and Asset Sale

Total liabilities at the end of 2025 were KRW 15.4 billion, below total equity of KRW 45.9 billion, and the debt ratio was 33.5%. The Daechi-dong property transfer, resolved in April 2026 for KRW 25.4 billion, was presented as a means of repaying debt and securing liquidity. How far the sale reduced debt can be checked in the borrowings section of the 2026 annual report.

Return to Operating Profit and Quarterly Recovery

Operating profit of KRW 1.4 billion in 2025 marked a return to profit, with an operating margin of 7.1%. In the second and third quarters of 2026, sales rose for two consecutive quarters and the operating loss narrowed in both. The narrowing loss each quarter can be read as a sign that sales recovery is beginning to absorb cost pressure.

Pursuit of Functional Claim Approvals

As of the third quarter of 2025, the company was pursuing Ministry of Food and Drug Safety approval for body-fat reduction and sensitive-skin immune improvement claims.

As the market shifts toward individually recognized probiotics, a company holding ingredients with recognized functional claims could gain an edge in negotiations with customers. The timing and result of the approvals have not yet been specified in any disclosure.

09

Bear factors

Continued Quarterly Operating Losses

The company posted operating losses for three consecutive quarters from the first quarter to the third quarter of 2026. First-quarter 2026 sales fell 48.3% quarter on quarter to KRW 2.5 billion, the low point.

The losses narrowed, but a third-quarter operating loss of KRW 68.78 million remained, so it is too early to say profitability has held quarter after quarter.

Intensifying Competition and Market Shift

Competition in the probiotics market is intensifying, and explanations cite lower finished-product and raw-material sales as the market shifts toward individually recognized probiotics. Those changes are linked to the weaker first half of 2026. If the product mix does not adapt to the regulatory shift, the sales recovery could remain limited.

Earnings Volatility and a Record of Consecutive Losses

Net losses attributable to controlling shareholders occurred in both 2024 and 2025. The sum of net income attributable to controlling shareholders over the last four quarters was KRW 2.04 billion, yet the fourth quarter of 2025 posted a KRW 914 million loss and the first quarter of 2026 a KRW 2.67 billion profit. Such wide quarter-to-quarter swings make it hard to say earnings have built up steadily.

10

Risk factors

Earnings Volatility

Sales swing sharply from quarter to quarter, falling from KRW 4.83 billion in the fourth quarter of 2025 to KRW 2.5 billion in the first quarter of 2026 before rising again. With a small sales base, order changes from one or two customers can weigh heavily on quarterly results.

Some quarters show operating and net results moving in different directions, so earnings quality needs to be read alongside the headline figures.

Approval and Regulation

The pending functional claim approvals have no disclosed outcome or timing. The shift to individually recognized ingredients can delay product launches depending on regulatory requirements. If approvals are delayed, expectations for new raw-material sales would also be pushed back.

Small-Cap Characteristics and Reliance on Asset Sales

Because the company is a small-cap, its share price can be volatile. Trading may be thin given its free-float structure. Much of the financial improvement depends on the property transfer, so whether operations can carry the debt after the sale is a task.

11

What to watch next

  1. December 31, 2026

    This is the close of the 2026 fiscal year. Whether the operating loss that ran from the first to the third quarter of 2026 narrows further in the fourth quarter, and whether sales hold near the KRW 4.27 billion level of the third quarter, are the year-end checks.

  2. March 31, 2027

    This is the statutory filing deadline for the 2026 annual report. It will show the annual operating margin, how much of the Daechi-dong sale proceeds went to debt repayment, and the breakdown of non-operating items.

  3. After January 2027, timing not set

    This is when preliminary full-year 2026 results may be disclosed. Preliminary figures precede the audited annual report and should be compared against the final values.

  4. Timing not set, upon approval disclosure

    These are the Ministry of Food and Drug Safety decisions on body-fat reduction and sensitive-skin immune improvement claims. Approval could change the sales terms for raw materials and finished products under the individually recognized framework.

12

Overall view

Bifido is showing signs of recovery, with a return to operating profit in 2025 and sales rising for two consecutive quarters in the second and third quarters of 2026.

On the other side, operating losses ran for three consecutive quarters from the first to the third quarter of 2026, and net losses attributable to controlling shareholders occurred in both 2024 and 2025.

The debt ratio at the end of 2025 was 33.5%, and all of the KRW 45.9 billion in total equity belongs to controlling shareholders, so the financial base is comparatively solid.

The Daechi-dong property transfer for KRW 25.4 billion, resolved in April 2026, was presented as a means of debt repayment and securing liquidity, and it could change the financial structure.

On the business side, rising competition in probiotics and the shift to individually recognized ingredients have pressured finished-product and raw-material sales. The pursuit of functional claim approvals is a variable for the next phase, but their outcome and timing have not been specified.

The next checks are the fourth-quarter results at the close of 2026, and the annual operating margin and debt repayment in the 2026 annual report due by the end of March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. digitaltoday.co.kr
  4. pharm.edaily.co.kr
  5. digitaltoday.co.kr
  6. ibtomato.com
  7. m.news.nate.com
  8. securities.miraeasset.com
  9. kr.investing.com
  10. kr.investing.com
  11. judal.co.kr
  12. money2.creontrade.com
  13. tradingkey.com
  14. judal.co.kr
  15. news.samsung.com
  16. judal.co.kr
  17. tambangnews.co.kr
  18. kr.investing.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis